The drug diABZI — which activates the body’s innate immune response — was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2. The findings by senior author Sara Cherry, PhD, professor of Pathology and Laboratory Medicine and the scientific director of the High-Throughput Screening (HTS) Core, were published this month in Science Immunology.
Read the Penn Medicine press release
World-renowned virologist William A. Haseltine commented in Forbes on the new study: "New Drug May Bypass SARS-CoV-2 Blockade Of Innate Immune Response"
Coverage in Consumer Affairs: "Penn researchers discover potential treatment"
A Molecular Cell article includes observations by the study's senior author, Dr. Sara Cherry, on "Working on SARS-CoV-2 during the pandemic"